• 1
    Ghosh AK,Smith NK,Prendiville J,Thatcher N,Crowther D,Stern PL. A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies. Eur cytokine Netw 1993; 4: 20511.
  • 2
    Smyth MJ,Cretney E,Kershaw MH,Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004; 202: 27593.
  • 3
    Atkins MB,Robertson MJ,Gordon M,Lotze MT,DeCoste M,DuBois JS,Ritz J,Sandler AB,Edington HD,Garzone PD,Mier JW,Canning CM, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3: 40917.
  • 4
    Gollob JA,Mier JW,Veenstra K,McDermott DF,Clancy D,Clancy M,Atkins MB. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6: 167892.
  • 5
    Motzer RJ,Rakhit A,Schwartz LH,Olencki T,Malone TM,Sandstrom K,Nadeau R,Parmar H,Bukowski R. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin Cancer Res 1998; 4: 118391.
  • 6
    Villarino AV,Huang E,Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol 2004; 173: 71520.
  • 7
    Yoshida H,Hamano S,Senaldi G,Covey T,Faggioni R,Mu S,Xia M,Wakeham AC,Nishina H,Potter J,Saris CJ,Mak TW. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001; 15: 56978.
  • 8
    Takeda A,Hamano S,Yamanaka A,Hanada T,Ishibashi T,Mak TW,Yoshimura A,Yoshida H. Role of IL-27/WSX-1 signaling for induction of T-Bet through activation of STAT1 during initial Th1 commitment. J Immunol 2003; 170: 488690.
  • 9
    Yoshida H,Hamano S,Miyazaki Y. The double identity of WSX-1 (Il-27R) as an initiator and attenuator of immune responses. Curr Immunol Rev 2005; 1: 5560.
  • 10
    Stumhofer JS,Laurence A,Wilson EH,Huang E,Tato CM,Johnson LM,Villarino AV,Huang Q,Yoshimura A,Sehy D,Saris CJ,O'shea JJ, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006; 7: 93745.
  • 11
    Batten M,Li J,Yi S,Kljavin NM,Danilenko DM,Lucas S,Lee J,de Sauvage FJ,Ghilardi N. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006; 7: 92936.
  • 12
    Yoshimura T,Takeda A,Hamano S,Miyazaki Y,Kinjyo I,Ishibashi T,Yoshimura A,Yoshida H. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol 2006; 177: 537785.
  • 13
    Wang S,Miyazaki Y,Shinozaki Y,Yoshida H. Augmentation of antigen-presenting and Th1-promoting functions of dendritic cells by WSX-1(IL-27R) deficiency. J Immunol 2007; 179: 64218.
  • 14
    Hisada M,Kamiya S,Fujita K,Belladonna ML,Aoki T,Koyanagi Y,Mizuguchi J,Yoshimoto T. Potent antitumor activity of interleukin-27. Cancer Res 2004; 64: 11526.
  • 15
    Shimizu M,Shimamura M,Owaki T,Asakawa M,Fujita K,Kudo M,Iwakura Y,Takeda Y,Luster AD,Mizuguchi J,Yoshimoto T. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006; 176: 731724.
  • 16
    Oniki S,Nagai H,Horikawa T,Furukawa J,Belladonna ML,Yoshimoto T,Hara I,Nishigori C. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006; 66: 6395404.
  • 17
    Chiyo M,Shimozato O,Iizasa T,Fujisawa T,Tagawa M. Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells. Anticancer Res 2004; 24: 37637.
  • 18
    Salcedo R,Stauffer JK,Lincoln E,Back TC,Hixon JA,Hahn C,Shafer-Weaver K,Malyguine A,Kastelein R,Wigginton JM. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J Immunol 2004; 173: 717082.
  • 19
    Wang YQ,Ugai S,Shimozato O,Yu L,Kawamura K,Yamamoto H,Yamaguchi T,Saisho H,Tagawa M. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 2003; 105: 8204.
  • 20
    Hu J,Yuan X,Belladonna ML,Ong JM,Wachsmann-Hogiu S,Farkas DL,Black KL,Yu JS. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006; 66: 888796.
  • 21
    Hogquist KA,Jameson SC,Heath WR,Howard JL,Bevan MJ,Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 1727.
  • 22
    Parkhurst MR,Fitzgerald EB,Southwood S,Sette A,Rosenberg SA,Kawakami Y. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998; 58: 4895901.
  • 23
    Bloom MB,Perry-Lalley D,Robbins PF,Li Y,el-Gamil M,Rosenberg SA,Yang JC. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185: 4539.
  • 24
    Hanada T,Yoshida H,Kato S,Tanaka K,Masutani K,Tsukada J,Nomura Y,Mimata H,Kubo M,Yoshimura A. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003; 19: 43750.
  • 25
    Inaba K,Inaba M,Romani N,Aya H,Deguchi M,Ikehara S,Muramatsu S,Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176: 1693702.
  • 26
    Colombo MP,Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 15568.
  • 27
    Hashimoto W,Osaki T,Okamura H,Robbins PD,Kurimoto M,Nagata S,Lotze MT,Tahara H. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol 1999; 163: 5839.
  • 28
    Wigginton JM,Wiltrout RH. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther 2002; 2: 51324.
  • 29
    Hamano S,Himeno K,Miyazaki Y,Ishii K,Yamanaka A,Takeda A,Zhang M,Hisaeda H,Mak TW,Yoshimura A,Yoshida H. WSX-1 Is Required for Resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 2003; 19: 65767.
  • 30
    Yamanaka A,Hamano S,Miyazaki Y,Ishii K,Takeda A,Mak TW,Himeno K,Yoshimura A,Yoshida H. Hyperproduction of Proinflammatory Cytokines by WSX-1-Deficient NKT Cells in Concanavalin A-Induced Hepatitis. J Immunol 2004; 172: 359096.
  • 31
    Holscher C,Holscher A,Ruckerl D,Yoshimoto T,Yoshida H,Mak T,Saris C,Ehlers S. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol 2005; 174: 353444.
  • 32
    Miyazaki Y,Inoue H,Matsumura M,Matsumoto K,Nakano T,Tsuda M,Hamano S,Yoshimura A,Yoshida H. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J Immunol 2005; 175: 24017.
  • 33
    Stumhofer JS,Silver JS,Laurence A,Porrett PM,Harris TH,Turka LA,Ernst M,Saris CJ,O'shea JJ,Hunter CA. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007; 8: 136371.
  • 34
    Fitzgerald DC,Zhang GX,El-Behi M,Fonseca-Kelly Z,Li H,Yu S,Saris CJ,Gran B,Ciric B,Rostami A. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007; 8: 13729.
  • 35
    Awasthi A,Carrier Y,Peron JP,Bettelli E,Kamanaka M,Flavell RA,Kuchroo VK,Oukka M,Weiner HL. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007; 8: 13809.
  • 36
    Hsu FJ,Benike C,Fagnoni F,Liles TM,Czerwinski D,Taidi B,Engleman EG,Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 528.
  • 37
    Tacken PJ,de Vries IJ,Torensma R,Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7: 790802.